Herpes Simplex Virus Stromal Keratitis
from OrphaChat — a Rare Disease Podcast Hosted by RCH
Recent medical research and clinical trials highlight significant progress in managing herpes simplex virus (HSV) and herpes zoster ophthalmicus (HZO). New investigational drugs like ABI-5366 and BD111 are showing promise in reducing viral shedding and treating stromal keratitis through innovative helicase-primase inhibition and CRISPR-Cas9 gene editing. Traditional therapies remain vital, as evidenced by the Zoster Eye Disease Study (ZEDS), which demonstrated that long-term valacyclovir use can decrease neuropathic pain and recurrent episodes. In addition to pharmaceutical advances, surgical interventions such as intrastromal injections and corneal transplants continue to evolve to prevent vision loss from scarring. Ultimately, these sources underscore a shift towards combined therapies and precision medicine to address the global burden of infectious blindness and chronic viral latency.
Embed this episode
No transcript yet.